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ABSTRACT
The adenosine receptor (AR) subtypes A2A and A2B are rhodopsin-like Gs protein-
coupled receptors whose expression is highly regulated under pathological, e.g. 
hypoxic, ischemic and inflammatory conditions. Both receptors play important roles in 
inflammatory and neurodegenerative diseases, are blocked by caffeine, and have now 
become major drug targets in immuno-oncology. By Förster resonance energy transfer 
(FRET), bioluminescence resonance energy transfer (BRET), bimolecular fluorescence 
complementation (BiFC) and proximity ligation assays (PLA) we demonstrated  
A2A-A2BAR heteromeric complex formation. Moreover we observed a dramatically 
altered pharmacology of the A2AAR when co-expressed with the A2BAR (A2B ≥ A2A) in 
recombinant as well as in native cells. In the presence of A2BARs, A2A-selective ligands 
lost high affinity binding to A2AARs and displayed strongly reduced potency in cAMP 
accumulation and dynamic mass redistribution (DMR) assays. These results have 
major implications for the use of A2AAR ligands as drugs as they will fail to modulate 
the receptor in an A2A-A2B heteromer context. Accordingly, A2A-A2BAR heteromers 
represent novel pharmacological targets. 
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 INTRODUCTION
Adenosine receptors (ARs) are G protein-coupled 
receptors (GPCRs) activated by the nucleoside adenosine. 
Four subtypes designated A1, A2A, A2B and A3ARs exist. A1 
and A3ARs preferentially couple to Gi/o proteins mediating 
inhibition of adenylate cyclase (AC) activity, while A2A 
and A2B receptors couple to Gs/olf proteins leading to AC 
activation and subsequent increase in cAMP formation 
[1]. In addition, A2B and A3ARs were shown to couple to 
Gq proteins which results in phospholipase C activation 
followed by a rise in inositol trisphosphate levels 
mediating intracellular calcium release [2–3]. The A2AAR 
is expressed in high density in the caudate-putamen, and 
at low levels in most other brain regions. In the periphery, 
the A2AAR is highly expressed in cells of the immune 
system and blood platelets, and at lower levels in many 
other cells and organs [4]. The A2BAR is broadly expressed 
but mostly at moderate to low levels. A2A and A2BARs 
are the most closely related AR subtypes with an overall 
sequence identity of 58% and a similarity of 73% [5]. 
They are co-expressed on many different cell types and 
in various organs and tissues, e.g. in heart [6], myeloid 
cells [7], T-cells [8], blood platelets [9], brown and white 
adipocytes [10], and in many tumors, e.g. neuroendocrine 
tumors [11], ovarian cancer [12], and prostate cancer 
                                                       Research Paper
Oncotarget13594www.impactjournals.com/oncotarget
[13]. The expression of A2A and A2BARs and their relative 
proportion can be markedly altered under pathological 
conditions [14]. For example, increased A2AAR expression 
is observed in the brains of patients suffering from 
neurodegenerative diseases [15], in multiple sclerosis and 
in amyotrophic lateral sclerosis [16–17]. Upon activation 
of T-lymphocytes the A2AAR is considerably upregulated 
[18]. On the other hand, the expression of A2BARs can 
be drastically increased in a hypoxia-inducible factor- 
(HIF1α-) dependent manner under hypoxic conditions, 
e.g. in inflamed or ischemic tissue, in tumors and cancer 
cells [19–20]. Hypoxia induction leads to a decrease in 
A2AAR expression while increasing A2BAR expression in 
human umbilical vein endothelial and bronchial smooth 
muscle cells. Pharmacological responses of A2A/A2BAR 
agonists were significantly altered in these cells [21]. The 
well investigated A2AAR subtype, the so-called “high-
affinity A2AR receptor”, is typically activated by relatively 
low (nanomolar) concentrations of adenosine, mediating 
potent anti-inflammatory and immunosuppressant as well 
as hypotensive and anti-psychotic effects [22]. In contrast, 
activation of the A2BAR subtype, the “low-affinity A2AR”, 
requires high, micromolar adenosine concentrations for 
activation [4]. Extracellular adenosine levels can rise from 
basal values of around 100 nM by up to 100-fold reaching 
concentrations of around 10 µM under pathological, i.e. 
hypoxic, ischemic or inflammatory conditions [1, 4, 23]. 
Cell death can lead to the formation of large amounts of 
extracellular adenosine through enzymatic degradation 
of released ATP by ectonucleotidases (CD39, CD73), 
e.g. in solid tumors [24]. Both anti- as well as pro-
inflammatory effects have been associated with the 
A2BAR [25], and the reasons for these contradictory results 
have remained obscure. The physiological significance 
of the A2BAR subtype is scarcely understood so far. 
During the last decade it has become well accepted that 
GPCRs are able to form di- or oligomeric assemblies 
of identical or distinct receptor monomers [26]. Most 
of these complexes have been detected in transfected 
living cells using well accepted biophysical techniques 
such as resonance energy transfer (bioluminescence and 
Förster resonance energy transfer, BRET and FRET) 
or bimolecular fluorescence complementation (BiFC) 
assays [27–28]. Proximity ligation assays (PLA) have 
been developed for identifying receptor heteromers in 
native cells and tissues [29]. Heteromer formation may 
modulate receptor pharmacology such as the affinity and 
potency of ligands or G protein coupling and signaling 
[30–31]. Recently, structural models of GPCR oligomers 
associated with G proteins have been built [32], and the 
development of heteromer-selective receptor ligands is 
becoming a promising new research area [33]. The A2AAR 
was reported to form homomeric receptor complexes as 
well as heteromers with several other GPCRs including 
dopamine D2 and D3, cannabinoid CB1, nucleotide P2Y1 
and P2Y2, and A1ARs [1]. Especially A2A-D2 heteromeric 
receptor complexes have been intensively studied since 
they play a significant role in Parkinson’s disease [34]. 
However, homo- or heteromer formation of the A2BAR 
subtype has not been demonstrated up to now. Based 
on the frequent co-expression of the closely related AR 
subtypes A2A and A2B, and considering the up-regulation of 
the A2BAR subtype and the up- or down-regulation of the 
A2AAR under many pathological conditions, the question 
arises if both receptors could form heteromers and whether 
this might affect their pharmacology and signaling. Here 
we demonstrate that A2A-A2BAR heteromers are formed 
in living cells by employing FRET, BRET and PLA, and 
their presence in native tissue was confirmed. Heteromer 
formation was found to be independent of the presence 
of agonists or antagonists, and does not require the long 
C-terminus of the A2AAR. Importantly, we demonstrate 
that A2A-A2B heteromerization is the reason for drastically 
altered pharmacology, in particular for the A2AAR, which 
is completely blocked by the presence of A2BAR protein. 
These results can now help to explain many unexpected 
or previously misinterpreted observations. They will be 
of high relevance for recently started drug development 
programs targeting A2A or A2BARs, in particular in 
neurodegenerative diseases and immuno-oncology.
RESULTS
FRET, BRET and BiFC experiments
FRET is a powerful technique for measuring 
protein-protein interactions in living cells [35]. To 
investigate a possible A2A-A2BAR interaction, FRET 
experiments were performed in Chinese hamster ovary 
(CHO-K1) cells transiently transfected with fusion 
proteins of green fluorescent protein variant 2 (GFP2) and 
enhanced yellow fluorescent protein (EYFP) attached 
to the C-terminus of the receptors [36] (Figure 1A–1C). 
The previously described A2A-homodimer and the fusion 
protein GFP²-EYFP were employed as positive controls 
showing FRET efficiencies of 0.23 and 0.44, respectively, 
similar to those previously reported (A2A homodimer: 
0.28, GFP²-EYFP: 0.52) (Figure 1A, 1B) [37]. The fusion 
protein GFP²-EYFP displayed a high FRET efficiency due 
to the very close proximity of donor and acceptor as a 
result of the short linker between both fluorophores. A 
clear FRET signal with an efficiency of 0.16 was observed 
in the co-transfected cells indicating the formation of 
A2A-A2B heteroreceptor complexes (Figure 1A). The pair 
A2AAR and GABAB2 receptor [36–37] was employed as 
a negative control; it showed a very low FRET signal 
demonstrating the specificity of the observed interactions 
(Figure 1A–1B). To gain insight into the potential A2A-
A2B heteromer interface, the C-terminal tail of the A2AAR 
was removed and the resulting construct A2A1-293R-
EYFP was studied in FRET experiments as an acceptor 
fluorophore in combination with the A2B-GFP² donor 
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fluorophore. The results indicated that the A2AAR that was 
lacking the C-terminal domain was still fully able to form 
heteromers with the A2BAR (FRET efficiency 0.24, Figure 
1B) suggesting that different receptor domains, possibly 
helical domains, have to be involved in heteromer 
formation. 
BRET is another biophysical technique that can 
be utilized to detect protein-protein interactions by 
measuring energy transfer from a bioluminescence donor 
to a fluorescent acceptor [35]. To confirm a direct A2A-
A2BAR interaction, BRET experiments were performed in 
living CHO-K1 cells transiently expressing fusion proteins 
Figure 1: Biophysical assays using A2A and A2BARs fused to FRET donor and acceptor. (A) FRET efficiencies were 
calculated by a sensitized emission method in living CHO cells transiently transfected with the different plasmids. Data are means ± SEM 
of 4–5 independent experiments performed in duplicates. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences 
in A2A-GFP² + A2A-EYFP (positive control) or A2B-GFP² + A2A-EYFP versus the negative control (A2A-GFP
2 + GABABR2-EYFP), 
**p 
< 0.01. As an internal control the fusion protein GFP2-EYFP was used. (B) FRET efficiencies determined in CHO cells transiently 
transfected with the different plasmids. The same controls were used as shown in (A). Data are means ± SEM of 5 independent experiments 
performed in duplicates. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences between A2A-GFP² + A2A-EYFP 
(positive control) or A2B-GFP² + A2A-1-293-EYFP versus the negative control (A2A-GFP
2 + GABABR2-EYFP), 
**p < 0.01. (C) Schematic 
representation of the performed FRET experiments with the different donor/acceptor pairs.
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consisting of a receptor (A2A, A2B, D2, or GABAB2) and 
Rluc (Renilla luciferase) or the fluorescent protein EYFP 
attached to the C-terminus (Figure 2A–2D). Three kinds of 
experiments were performed as shown in Figure 2A, 2C and 
2D. For BRET saturation curves cells were co-transfected 
with a constant amount of cDNA for Rluc-receptor constructs 
and increasing concentrations of cDNAs for EYFP-receptor 
constructs. As a widely accepted positive control for GPCR 
dimers, donor/aceptor proteins having the dopamine D2R-
A2AAR were used. The results showed a high BRET signal 
displaying a hyperbolic curve, with a BRET50 value of 239 
± 40  and a BRETmax value of 144 ± 6 mBU. As a negative 
control, donor/acceptor proteins having the A2AAR and 
GABAB2 receptor pair were used. The combination of A2A 
and A2BARs resulted in a specific BRET signal which was 
even higher than the positive control indicating a specific 
interaction of both receptors. A BRET50 value of 122 ± 6 
and a BRETmax value of 158 ± 10 mBU were determined 
(Figure 2A). Subsequently, a BRET displacement study 
was performed in which increasing amounts of unlabeled 
A2BAR were added to A2B-Rluc and A2A-YFP receptors. 
The experiment showed a significant decrease in the 
BRET signal, which was dependent on the added amount 
of unlabeled A2BAR (Figure 2C), indicating displacement 
by the unlabeled receptor of the Rluc-tagged A2BAR in the 
heteromer. As a final step, potential effects of A2A and A2BAR 
agonists and antagonists on A2A-A2B heteromer formation 
were studied. The BRET signal after 60 min of treatment 
with agonists (adenosine, nonselective; NECA, nonselective; 
CGS-21680, A2A-selective; BAY60–6583, A2B-selective) or 
Figure 2: Biophysical assays using A2A and A2BARs fused to BRET donor and acceptor. (A) BRET saturation curves: 
CHO-K1 cells were transiently co-transfected with a constant amount of A2A, A2B or D2 receptors fused to Rluc and increasing amounts of 
cDNA for A2A or GABAB2 receptors fused to EYFP. BRET experiments were performed in duplicates for A2B-Rluc and A2A-YFP (▲) (n 
=11) with a BRETmax = 158 ± 10 mBU and BRET50 = 122 ± 58, positive control D2-Rluc and A2A-YFP (●) (n = 15) BRETmax = 144 ± 6 
mBU and BRET50 = 239 ± 40, and negative control A2A-Rluc and GABAB2-YFP (♦) (n = 13). (B) Schematic representation of the BRET 
experiments. (C) BRET competition experiments were performed (n = 4, in triplicates) in cells transfected with 1.25 µg of cDNA for 
A2B-Rluc, 2.5 µg of cDNA for A2A-YFP and increasing amounts of cDNA for untagged A2BARs. The one-way ANOVA with Dunnett’s 
post-hoc test showed a significant decrease in the BRET signal compared to cells which were not transfected with untagged A2BARs (green 
column; *p < 0.05; **p < 0.01). (D) CHO cells were transiently co-transfected with 2 µg of cDNA for A2B-Rluc and 3 µg of cDNA for A2A-
YFP. Different agonists (adenosine, NECA, CGS-21680, BAY60-6583) and antagonists (PSB-603) were added and the BRET signal was 
measured over a time period of 60 min (n = 3, in duplicates). 
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the A2B antagonist PSB-603 was similar to that obtained 
in the absence of ligands (Figure 2D), thus indicating that 
A2A-A2B heteromer formation was not influenced by those 
receptor ligands. 
These results were further corroborated by BiFC 
experiments, which provided strong evidence for a very 
close interaction between  A2A and A2BARs (Supplementary 
Figures 1, 2).
In situ proximity ligation experiments in the rat 
brain
The PLA combines the high specificity and 
affinity of antibodies (PLA probe) with the sensitivity 
of quantitative polymerase chain reactions (PCR) to 
detect proteins that are forming molecular complexes 
in native sources [38]. Initially we studied the 
recombinant CHO-A2A-A2B cell line to investigate the 
receptors’ proximity (Supplementary Figure 3A–3C) 
and obtained small, brightly green fluorescent spots 
each of which represents a single A2A-A2BAR heteromer 
(Supplementary Figure 3C). Next we performed in situ 
PLA focusing on the dorsal hippocampus of the rat brain 
(Figure 3, Supplementary Figures 4, 5) where moderate 
to high densities of PLA-specific clusters were found. It 
should be noted that the molecular layer of the dentate 
gyrus lacked PLA clusters, and the unspecific labeling 
there was similar to that observed in negative control 
sections obtained by omitting the primary anti-A2A 
antibody. Furthermore, few PLA positive clusters were 
observed in the oriens of the CA1 areas. In contrast, a 
high density of A2A-A2B specific clusters was found in 
the CA3 pyramidal cell layer, mainly in perisomatic 
location (Figure 3), where PLA-positive clusters had 
diameters from 0.5–2 µm. They were present also in 
lower densities in the radiatum and oriens. In all these 
regions PLA positive clusters were also found in the 
neuropil. The CA1 showed a similar distribution pattern 
(as compared with CA3), with high dot/cluster densities 
within the pyramidal cell layer. An important difference 
was, however, the diameter range of the clusters, which 
appeared to be reduced in this CA1 region versus CA3 
(Supplementary Figure 4). 
In the polymorphic layer of the dentate gyrus 
(PoDG), a high density of specific A2A-A2B clusters was 
observed in both perisomatic and neuropil position. The 
range of diameter size in the clusters was similar to that in 
the CA3 area (Supplementary Figure 5).
Figure 3: In situ proximity ligation assay in rat hippocampus. A2A-A2BAR-specific PLA clusters in the CA3 region of the dorsal 
hippocampus of the rat (Bregma: –3.6 mm).  The sampled region is taken from the framed section of the dorsal hippocampus in the upper 
right corner of the figure. The microphotographs taken are based on 20 Z-scans (1 µm each). The nuclei are shown in blue. A high density 
of PLA positive clusters in red are visualized mainly in the pyramidal cell layer shown also in higher amplification in the panel at the 
lower right part of the figure. A few are indicated by arrows. The diameter range of the clusters is 0.5–2 µm. They are mainly located in a 
perisomatic position around the blue nuclei but also in the neuropil. A low density of specific PLA clusters is also found in the radiatum 
and oriens close to the pyramidal cell layer.
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Pharmacological implications of A2A-A2BAR 
heteromer formation
To study the pharmacology of A2A-A2BAR 
heteromers, native as well as recombinant cell lines were 
investigated. Expression levels of A2A and A2BARs were 
analyzed by reverse transcriptase (RT) PCR, Western blot 
analysis and radioligand binding studies (Supplementary 
Figure 6A–6E). Recombinant cell lines were prepared to 
control the proportion of A2A and A2BAR expression (A2B ≥ 
A2A, and A2A > A2B) (Supplementary Table 1).
Radioligand-receptor binding studies
Radioligand binding studies were performed 
using the A2B-selective antagonist radioligand [³H]
PSB-603 and two A2A-selective radioligands, the 
antagonist [³H]MSX-2, and the agonist [³H]CGS-
21680 (Supplementary Figure 7A–7C, Supplementary 
Table 2). A selective radiolabeled agonist for A2BARs 
is currently not available. Labeling of A2BARs with 
[³H]PSB-603 demonstrated high A2B expression in 
membrane preparations of CHO-A2B and CHO-A2A-A2B 
(A2B ≥ A2A) cell lines both of which displayed similar 
A2B expression levels (502 and 418 fmol/mg protein, 
respectively). Jurkat-T (220 fmol/mg protein) and HeLa 
cells (80 fmol/mg protein) had lower A2BAR expression 
levels (Supplementary Figure 6E, Supplementary 
Table 2). As expected, in cells lacking significant A2B 
expression (CHO-K1, CHO-HA-A2A, HEK-A2A), no 
high-affinity binding of the A2B-selective antagonist 
radioligand [³H]PSB-603 was observed (Supplementary 
Figure 7C). In cells that co-expressed both receptors 
(CHO-A2A-A2B cells, HeLa cells, Jurkat-T cells, native 
human T-lymphocytes), specific binding of [³H]PSB-
603 was detected, and its affinity was similar to that 
determined at CHO cells expressing only A2BARs 
(Supplementary Figure 8A, Supplementary Table 
2). Native primary human lymphocytes displayed a 
moderate expression level of A2BARs, lower to that of 
A2AARs. Upon activation with phytohemagglutinin 
(PHA), the A2B expression level remained virtually 
unaltered (Supplementary Figure 9). All radioligand 
binding results on A2BARs were in agreement with the 
data obtained in RT-PCR and Western blot experiments 
(Supplementary Figure 6A–6D, Supplementary Table 
2). The A2A-selective radioligands [
3H]MSX-2 and [3H]
CGS-21680 labeled A2AARs in CHO-A2A cells and in 
cells expressing more A2A- than A2BARs (Figure 4, 
Supplementary Figure 7A, 7B, Supplementary Table 2). 
Native primary human lymphocytes displayed specific 
binding of [3H]MSX-2 indicating A2AAR expression, 
that was significantly upregulated (by about 4-fold) 
upon activation with PHA (Supplementary Figure 9, 
Supplementary Table 2). Unexpectedly, in cells with 
similar or higher expression of A2B as compared to 
A2AARs no high-affinity binding of either A2A-selective 
radioligand, [3H]MSX-2 or [3H]CGS-21680, was 
observed (Supplementary Figure 8A, 8B, Supplementary 
Table 2). Competition binding assays versus [3H]PSB-
603 were performed to determine the A2B affinity of 
selected agonists and antagonists while A2A affinity of 
compounds was determined versus [3H]MSX-2. Indeed, 
the latter was only possible in cell lines expressing more 
A2A than A2BARs since high affinity binding of the A2A-
selective radioligands was abolished when A2B receptors 
were co-expressed (see above). 
CHO-A2A and CHO-A2B cell lines displayed the 
expected affinities of agonists and antagonists typical 
for, respectively, A2A or A2BARs (Figure 4A, 4B, 
Supplementary Table 3). In CHO-A2A-A2B cell membranes, 
which showed a similar or slightly higher expression of 
A2B than of A2AARs, the agonists adenosine, NECA, and 
BAY60-6583 and the antagonists PSB-603 and caffeine 
displayed only slightly modulated A2B affinities (Figure 
4A, 4B, Supplementary Table 3). We subsequently 
studied a T-cell line, namely Jurkat-T cells, which express 
similar amounts of A2A and A2BARs, the level of which 
is, however, lower than in the recombinant CHO-A2A-
A2B cells. The A2B-selective radioligand [
3H]PSB-603 
displayed high affinity binding which was displaced by 
the A2B-selective partial agonist BAY60-6583 (Figure 4C, 
Supplementary Figure 8A, Supplementary Tables 2, 3). 
However, no high-affinity binding was observed for the 
A2A-selective radioligands [³H]MSX-2 and [³H]CGS-
21680 (Supplementary Figure 8A, 8B, Supplementary 
Table 2), although we could clearly detect A2AAR protein 
expression in Jurkat-T cells (Supplementary Figure 6C). In 
native T-lymphocytes, isolated from healthy human blood 
donors, the expression of the A2AAR was higher than that 
of the A2BAR (Supplementary Figure 9, Supplementary 
Table 2). High affinity binding was then observed for the 
A2A-selective radioligand [
3H]MSX-2 as well as for the 
A2B-selective radioligand [
3H]PSB-603 (Supplementary 
Figure 8A, 8B, Supplementary Table 2). In HeLa cells, 
which natively express more A2B than A2AARs, again, 
no high-affinity binding was obtained for the A2A-
selective radioligands [³H]MSX-2 and [³H]CGS-21680 
(Supplementary Figure 8A, 8B, Supplementary Table 2) 
although we could clearly detect the A2AAR protein in this 
cell line (Supplementary Figure 6D). As a next step we 
overexpressed the human A2AAR containing an HA tag in 
HeLa cells to obtain a cell line which expressed more A2A 
than A2BARs (Supplementary Figure 6D, Supplementary 
Table 2). This led to the recovery of high-affinity 
binding for the A2A-selective radioligands (Figure 4D, 
Supplementary Table 2). NECA and CGS-21680 showed 
higher affinity versus the agonist radioligand than versus 
the antagonist radioligand, whereas the antagonist MSX-
2 displayed similar affinities versus both radioligands 
(Figure 4D, Supplementary Table 3), results that are 
typical for A2AARs [39]. 
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cAMP accumulation assays
A2A and A2BARs are coupled to Gs proteins, 
activating adenylate cyclase. Thus, cAMP accumulation 
assays were performed at CHO cells stably expressing the 
A2AAR, the A2BAR, or both. Adenosine increased cAMP 
accumulation with an EC50 value of 174 nM in CHO 
cells expressing the “high affinity” A2AAR, and with an 
EC50 value of 12,500 nM in CHO cells expressing the 
“low-affinity” A2BAR. The CHO-A2A-A2B cell line co-
expressing both subtypes showed virtually the same EC50 
value (13,100 nM) as the cell line only expressing A2BARs 
(Figure 5A, Supplementary Table 4). The metabolically 
more stable adenosine analog NECA displayed a similar 
behaviour. The potent A2A-selective agonist CGS-21680 
(EC50 16.6 nM in CHO-A2A cells) was inactive in CHO-
A2A-A2B cells (EC50 > 10,000 nM). In contrast, the A2B-
selective partial agonist BAY60-6583 (EC50 165 nM 
in A2BAR-expressing cells) had similar potency in the 
A2A-A2B-coexpressing cell line (EC50 193 nM) (Figure 
5A, Supplementary Table 4). Antagonist potencies were 
determined by measuring concentration-response curves 
for the non-selective agonist NECA in the presence or 
absence of different antagonists, and KB values were 
calculated. The A2B-selective antagonist PSB-603 and 
the non-selective antagonist caffeine showed very similar 
KB-values at CHO-A2A-hA2B (PSB-603, KB 0.673 nM; 
caffeine, KB 9,900 nM) as at CHO-A2B cells (PSB-603, 
KB 0.358 nM; caffeine, KB 15,600 nM) (Figure 5B, 
Supplementary Table 4). 
We next employed Jurkat-T cells as a native cell 
line expressing similar amounts of A2A and A2BARs. These 
cells behaved like the CHO-A2A-A2B cell line displaying 
moderate potency for the physiological agonist adenosine 
and the structurally related agonist NECA. Again, CGS-
21680 was inactive at concentrations up to 10 µM, while 
the A2B-selective antagonist PSB-603 and the nonselective 
antagonist caffeine displayed KB-values in the same 
Figure 4: Affinities of AR agonists and antagonists in different cells expressing A2A and A2BARs. (A) Competition binding 
experiments of agonists versus 1 nM [³H]MSX-2 at A2A-expressing membranes, and versus 0.3 nM [³H]PSB-603 at A2B- and at A2A-A2BAR-
expressing membranes of CHO cells. The two-tailed t-test showed significant differences. ***p < 0.001, **p < 0.01, n = 2–3, see also 
Supplementary Table 3. (B) Competition binding experiments of AR antagonists versus 1 nM [³H]MSX-2 at A2A-expressing, and versus 
0.3 nM [³H]PSB-603 at A2B - and at A2A-A2BAR co-expressing CHO cell membranes. The two-tailed t-test showed significant differences. 
***p < 0.001, *p < 0.1, n = 3, see also Supplementary Table 3. (C) Competition binding experiments of AR agonists and antagonists 
versus 0.3 nM [³H]PSB-603 at Jurkat-T and HeLa cell membranes, n = 3–6, see also Supplementary Table 3. (D) Competition binding 
experiments agonists and antagonists versus 5 nM [³H]CGS-21680, and versus 1 nM [³H]MSX2, respectively, at HeLa cell membranes 
recombinantly overexpressing A2AARs. The two-tailed t-test showed significant differences. ns: not significant, 
***p < 0.001, n = 3–4, see 
also Supplementary Table 3.
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range as those determined at CHO-A2B cells (Figure 5C, 
Supplementary Table 4). 
cAMP assays at HEK-A2A cells transiently 
transfected with increasing amounts of A2BAR
Next, the effect of the expression of different 
amounts of A2BARs on A2AAR pharmacology was studied. 
To this end human embryonic kidney (HEK293T) cells 
stably expressing the human A2AAR were transfected with 
human A2BAR cDNA to transiently express increasing 
amounts of A2BARs. The A2B-selective agonist BAY60-
6583 (100 nM) showed a significant increase in cAMP 
accumulation with increasing amounts of transiently 
transfected A2BARs confirming functionality of the 
A2BAR (Figure 6A). In contrast, when stimulating the 
cells with the A2A-selective agonist CGS-21680 (100 nM), 
a significant decrease in cAMP accumulation with 
increasing amounts of the transiently transfected A2BAR 
was observed suggesting an inhibition of the A2AAR 
Figure 5: cAMP accumulation in recombinant CHO cell lines and in Jurkat-T cells.  (A) pEC50 values of AR agonists in 
cAMP accumulation assays in CHO-A2A, CHO-A2B and CHO-A2A-A2B cells. The one-way ANOVA with Dunnett’s post-hoc test indicated 
significant differences. ns: not significant, **p < 0.01, n = 2–4, see also Supplementary Table  4. The A2AAR agonist CGS-21680 showed 
only a negligible signal in CHO-A2A-A2B cells at concentrations of up to 100 µM. (B) pKB values for AR antagonists in cAMP accumulation 
assays in CHO-A2A, CHO-A2B and CHO-A2A-A2B cells with agonist stimulation by NECA. The one-way ANOVA with Dunnett’s post-hoc 
test showed significant differences. ns: not significant, **p < 0.01, n = 4–6, see also Supplementary Table  4. (C) pEC50 values of agonists 
and pKB values of antagonists determined in cAMP accumulation assays at Jurkat-T cells (n = 3, see also Supplementary Table 4).
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Figure 6: cAMP determination in cells coexpressing variable proportions of A2A and A2BARs. (A) Stimulation of cAMP 
accumulation induced by 100 nM of the A2B-selective partial agonist BAY60-6583 at HEK-A2A cells transiently transfected with increasing 
amounts of cDNA for A2BAR (0.25–1.5 µg). The basal cAMP level, i.e. HEK-A2A cells only with medium but without the agonist, was 
set at 100%. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences. ns: not significant, **p < 0.01 (n = 2, in 
triplicates). (B) Stimulation of cAMP accumulation induced by 100 nM of the A2A-selective agonist CGS-21680 at HEK-A2A cells transiently 
transfected with increasing amounts of cDNA for A2BAR (0.25–1.5 µg). Basal cAMP, i.e. HEK-A2A cells only with medium but without the 
agonist, was set at 100%. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences. ns: not significant, *p < 0.05, 
**p < 0.01 (n = 2, in triplicates).  (C) Stimulation of cAMP accumulation induced by a combination of 100 nM of the A2A-selective agonist 
CGS-21680 and of 100 nM of the A2B-selective partial agonist BAY60-6583 at HEK-A2A cells transiently transfected with with increasing 
amounts of cDNA for A2BAR (0.25–1.5 µg). Basal cAMP, i.e. HEK-A2A cells only with medium but without the agonist, was set at 100 
%. The one-way ANOVA with Dunnett’s post-hoc test showed significant differences. ns: not significant, **p < 0.01 (n = 2, in triplicates).
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through the A2BAR (Figure 6B). Stimulation of the cells 
with a combination of both receptor subtype-selective 
agonists (100 nM each), showed a significant increase 
in cAMP accumulation with increasing amounts of 
transiently transfected A2BAR additionally suggesting a 
dominant role for the A2BAR (Figure 6C).
Dynamic mass redistribution assays
Finally, dynamic mass redistribution (DMR) assays 
providing a holistic readout were performed in HEK293T 
cells transiently transfected with different ratios of A2A and 
A2BAR cDNA. The A2B-selective agonist BAY60-6583 
(100 nM) displayed a time-dependent increase in the signal 
with increasing amounts of transiently transfected A2BAR 
confirming the presence of functional A2BARs (Figure 
7A). In contrast, when stimulating the cells with the 
A2A-selective agonist, CGS21680 (100 nM), a time-
dependent decrease in signal was observed with increasing 
amounts of transiently transfected A2BAR suggesting an 
inhibition of the A2AAR-mediated DMR signal through 
the A2BARs (Figure 7B). Stimulation of the cells with 
a combination of both, A2A and A2BAR agonist (100 
nM each), showed a significant increase in signal with 
increased amounts of transiently transfected A2BAR, 
but not with increased amounts of A2AAR, additionally 
suggesting within the heteromer a dominant role for the 
A2BAR (Figure 7C). 
DISCUSSION 
Adenosine is an important signaling molecule, and 
the A2A and A2BAR subtypes are established (A2A) or 
potential (A2B) drug targets. Both receptors are Gs protein-
coupled, but the A2BAR requires much higher adenosine 
concentrations to be activated than the A2AAR, and its 
physiological role remains enigmatic. In the present study 
we demonstrate that A2BARs physically interact with 
A2AARs forming A2A-A2B heteromers. This interaction leads 
to new signalling properties as observed in cAMP 
experiments at Jurkat-T and further native and recombinant 
cells. Although A1, A2A and A3 homomeric ARs and several 
heteromers of A1 and A2AARs had previously been 
described [1, 40–41], neither homo- nor heteromers of 
A2BARs have been unambiguously demonstrated so far. Our 
study was motivated (i) by the fact that A2A and A2BARs are 
frequently co-expressed; (ii) by the observation that A2AAR 
pharmacology appears to be strikingly different than 
expected in a number of A2A-A2B co-expressing cells and 
tissues, (iii) by the still unknown physiological role of the 
“low-affinity” A2BARs; (iv) by contradictory results on pro- 
or anti-inflammatory effects mediated by the A2BAR, and 
(v) by the observation that A2A and A2BARs upon activation 
– although they are both Gs protein-coupled – often show 
opposite effects [25]. A2A-A2B heteromerization had 
previously been postulated to be required for high A2BAR 
expression, and the C-terminus of the A2AAR has been 
suggested to play an important role in this respect [42]. 
However, we could not confirm the published results. In 
fact, high A2BAR expression is observed in many cancer 
cells including those which express lower amounts of 
A2AARs [12–13, 43–45]. Nevertheless, co-
immunoprecipitation experiments on A2A-A2BAR-
coexpressing HEK293 cells had provided the first 
indication of a possible existence of A2A-A2B heteromers 
[42]. In the present study, by applying several 
complementary techniques, we provide compelling 
evidence that A2A and A2B form heteromeric di-/oligomers 
in recombinant as well as in native cells and tissues. FRET 
experiments confirmed specific interaction between both 
receptor subtypes (Figure 1A). So far the structure of the 
heteromers and their interaction surface is still unknown. In 
the well-characterized A2A-D2 heteromer the long 
C-terminus of the A2AAR is involved in heteromerization 
[46]. To gain insight into the A2A-A2B heteromer interface, 
we removed the C-terminus of the A2AAR and examined the 
resulting truncated receptor mutant co-expressed with the 
A2BAR in FRET experiments. The observed FRET signal 
was comparable to the one obtained for the wt A2A-A2BAR 
heteromer (Figure 1A, 1B) indicating that the C-terminus is 
not involved in the formation of A2A-A2B heteromers. 
Extensive BRET studies, including displacement 
experiments with untagged receptors, showed high, specific 
BRET signals for the A2A-A2BAR pair (Figure 2A, 2C). 
Incubation of cells with various agonists, adenosine 
(nonselective), NECA (nonselective), CGS-21680 (A2A-
selective), BAY60-6583 (A2B-selective), or antagonists 
(PSB-603, A2B-selective) did not lead to a significant 
change of the signal (Figure 2D). This means that A2A-A2B 
heteromer formation is independent of the presence of A2A 
or A2BAR ligands and stable in the presence of ligands. 
Furthermore BiFC experiments in which part of the EYFP 
sequence is attached to the A2A, the other part to the A2BAR, 
resulted in positive signals. These data convincingly 
underscore that both receptors are directly interacting, and 
that an A2A-A2B heterodi- or -oligomer must have been 
formed (Supplementary Figures 1, 2). A2A-A2B heteromer 
formation in CHO-A2A-A2B cells was confirmed by yet 
another technique, proximity ligation assays (PLA), using 
specific modified primary antibodies. The positive PLA 
signals obtained in living CHO-A2A-A2B cells, but not in 
non-transfected CHO cells, indicated close proximity of 
both receptors in the CHO cell line that coexpress them 
(Supplementary Figure 3). Thus, all conducted biophysical 
and biochemical techniques, namely FRET, BRET, BiFC 
and PLA studies, provided evidence that A2A and A2BARs 
can form heteromers in living cells. Importantly, the 
existence of A2A-A2B heteromers in native tissues was 
confirmed by using the PLA approach (Figure 3, 
Supplementary Figures 4, 5) thus proving their 
physiological relevance. Remarkably, heteromers were 
detected in sections from hippocampus of the rat. Receptor 
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pharmacology was altered in cells expressing the two 
receptors and, therefore, also expressing A2A-A2B 
heteromers, as compared to that in cells expressing only one 
receptor subtype. This was initially observed in a 
recombinant system investigating CHO-A2A, CHO-A2B and 
CHO-A2A-A2B cells, the latter of which had higher A2B than 
A2AAR expression as assessed by RT-PCR and Western blot 
analysis. In cell lines only expressing A2A or A2BARs, 
radioligand binding studies provided the expected affinities 
for standard ligands, i.e. high affinity binding of the 
selective A2AAR ligands CGS-21680 (agonist) and MSX-2 
(antagonist), but lacking affinity for the A2B-selective 
Figure 7: Label-free assays in cells coexpressing variable proportions of A2A and A2BARs. (A) Time-dependent dynamic 
mass redistribution (DMR) measurement induced by 100 nM of the A2B-selective partial agonist BAY60-6583 in HEK293T cells transiently 
transfected with a constant amount of cDNA for A2AAR and increasing amounts of cDNA for A2BAR, or vice versa, a constant amount of 
cDNA for A2BAR and increasing amounts of cDNA for A2AAR. (B) DMR measurement induced by 100 nM of the A2A-selective agonist 
CGS-21680 in HEK293T cells transiently transfected with a constant amount of cDNA for A2AAR and increasing amounts of cDNA for 
A2BAR, or vice versa, a constant amount of cDNA for A2BAR and increasing amounts of cDNA for A2AAR. (C) DMR measurement induced 
by a combination of 100 nM of the A2A-selective agonist CGS-21680 and of 100 nM of the A2B-selective partial agonist BAY60-6583 at 
HEK293T cells transiently transfected with a constant amount of cDNA for A2AAR and increasing amounts of cDNA for A2BAR, or vice 
versa, a constant amount of cDNA for A2BAR and increasing amounts of cDNA for A2AAR.
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ligands BAY60-6583 (partial agonist) and PSB-603 
(antagonist) at the CHO-A2A cells and vice versa for the 
CHO-A2B cells (Supplementary Tables 2, 3). At the CHO-
A2A-A2B cell line, however, no binding for the A2A-selective 
radioligands [³H]MSX-2 and [³H]CGS-21680 was detected 
although we could clearly prove both the presence of 
A2AAR mRNA and A2AAR protein in this cell line 
(Supplementary Figures 8A, 8B, 6A, 6B, Supplementary 
Table 2) and its cell surface localization (Supplementary 
Figure 3C). The A2A-A2B heteromer behaved almost like an 
A2BAR by displaying low affinity for adenosine and NECA 
(Figure 4A, 4B), high affinity for PSB-603 and no 
significant sign of A2AAR activation. cAMP accumulation 
assays yielded results in line with the pharmacology 
obtained in binding studies (Figure 5A–5C, Supplementary 
Table 4). Moreover in cAMP assays as well as in DMR 
assays at HEK-A2A cells transiently transfected with 
increasing amounts of the A2BAR (Figure 6A–6C, Figure 
7A–7C) a clear inhibiton of A2AAR function through 
A2BARs could be demonstrated. This means that the A2AAR 
signaling appears to be completely blocked in the A2A-A2B 
heteromer. On a molecular level, this would mean that the 
A2BAR modulates the conformation of the binding site of 
the A2AAR in such a way that it either loses its affinity for 
ligands completely, and only the A2B binding site is 
available for interaction with ligands, or the A2A binding site 
in the heteromer switches to A2B-like properties. Both 
would in principle be possible. In fact, the binding sites for 
adenosine in A2A and A2BARs are almost identical differing 
only in a single amino acid (A2A: L249, A2B: V250), and yet 
their affinity for adenosine is very different. It is therefore 
likely that the ligand binding site of A2A and A2BARs is 
readily amenable to allosteric modulation. The discovery of 
A2AAR action blockade by the A2BAR was very consistent 
when assayed in heterologous expression systems, in cell 
lines or in primary cells. Other groups had previously 
confirmed A2A and A2B mRNA expression in Jurkat-T cells 
(A2B ≥ A2A) and discovered that the selective A2AAR agonist 
CGS-21680 was nearly inactive in cAMP assays [47], and 
also the binding of [³H]CGS-21680 (12.5 nM) to Jurkat-T 
cell membranes was found to be negligible [48]. These 
results can now be explained by taking into account our 
discovery that the A2AAR is non-functional within the A2A-
A2B heteromer context present in Jurkat-T cells. Our 
findings also provide a mechanistic basis to interpret 
previous results, namely the altered AR pharmacology in 
cells expressing both A2B and A2AARs with similar or higher 
levels of A2B (A2B ≥ A2A). In Supplementary Table 5 we 
have collected the appropriate literature data that may now 
be interpreted in the light of our main finding. For example, 
in the human bladder carcinoma cell line T24 the expression 
of A2B and A2A receptors was demonstrated by RT-PCR (A2B 
> A2A). In cAMP assays NECA and adenosine were able to 
induce cAMP accumulation whereas the A2A-selective 
agonist CGS-21680 was inactive [45]. Wei et al. showed 
expression of all four AR subtypes in three prostate cancer 
cell lines by qRT-PCR and Western blot experiments, with 
domination of the A2BAR (A2B > A2A). NECA and the 
selective A2BAR agonist BAY60-6583, but not the A2A-
selective agonist CGS-21680, concentration-dependently 
induced cAMP accumulation [13]. Recently, Hajiahmadi 
et al. demonstrated expression of all four AR subtypes in 
three human ovarian cancer cell lines by qRT-PCR and 
Western blot, in which, again, the A2BAR was the most 
abundant one (A2B > A2A), and NECA but not the A2AAR 
agonist CGS-21680, concentration-dependently induced 
cAMP accumulation [12]. In contrast, in A2A-A2B-co-
expressing cell lines and tissues in which the expression 
level of A2AARs is higher than that of A2B (A2A > A2B), e.g. 
in T-lymphocytes from human blood, PC12 cells, or HMC-
1 cells, canonical A2A and A2B pharmacology is observed 
(Supplementary Tables 2, 5) [8, 16, 49–50]. It is likely that 
A2A-A2BAR heteromers exist in these cells but in a 
proportion that does not prohibit activation of free A2AARs 
(that cannot be blocked by A2BARs). Thus, regulation of A2A 
and A2B expression levels can in turn govern the 
pharmacological outcome of stimulation with adenosine or 
synthetic AR agonists. Both Gs-coupled A2AR subtypes 
play important (patho)physiologic roles and are co-
expressed on many cell types and tissues [6, 8, 11, 51]. Up-
regulation of A2AAR expression in different tissues can be 
found under various pathological conditions. For example, 
lymphocytes from amyotrophic lateral sclerosis (ALS) or 
multiple sclerosis (MS) patients show increased A2AAR 
levels [16–17]. NF-kappaB was found to enhance hypoxia-
driven T-cell immunosuppression via activation of 
upregulated A2AARs [52]. In a study on isolated perfused 
mouse heart investigating the contributions of A2A and 
A2BARs on cardiac flow, the A2A-selective agonist CGS-
21680 and the non-selective agonist NECA increased 
coronary flow in A2B knockout (KO) mice to a significantly 
higher degree than in wildtype (WT) mice [51]. The A2A-
selective antagonist SCH58261 blocked NECA-induced 
increase in coronary flow to a higher degree in KO than in 
WT mice. The authors explained these discrepancies by an 
observed upregulation of A2AARs (ca. 20% as estimated by 
Western blot) in mesenteric arterioles of KO as compared 
to WT mice. However, an additional or alternative 
explanation could be that by deletion of A2BARs, heteromer 
formation would no longer be possible leading to a de-
blocking of the A2AARs and thus a higher number of free 
receptors with typical A2A pharmacology. Several studies 
have led to the proposal that GPCR heteromers may 
constitute drug targets in their own right and that heteromers 
can be upregulated in disease [53]. It appears that A2A and 
A2BARs display very high affinity for each other, and 
whenever they are co-expressed they would form stable 
heteromers with a distinct pharmacology. This implies that 
the A2A-A2B interface and the interactions must be unique to 
produce such a remarkable and persistent disappearance of 





For FRET experiments the cDNAs of the human 
A2AAR and the C-terminal truncated mutant A2A1-293R 
were amplified by PCR using primers that delete the stop 
codon of the receptors and introduce EcoRI and AgeI 
restriction enzyme sites. The resulting PCR products 
were cloned in-frame with EcoRI/AgeI into the vectors 
pEYFP-N1 and pGFP²-N3, respectively. The cDNA of the 
human A2BAR was also cloned with EcoRI/AgeI into the 
vector pGFP²-N3. For a positive control a fusion protein 
GFP²-EYFP was used. The cDNA of GFP² was amplified 
by PCR using primers that delete the stop codon of the 
protein and introduce BamHI and AgeI restriction enzyme 
sites. The resulting PCR product was cloned in-frame 
with BamHI/AgeI into pEYFP-N1 plasmid, respectively. 
The cDNA of the GABABR2-EYFP receptor construct 
was a gift from Prof. Franco. For BRET experiments 
the cDNAs of the human A2A and A2BAR were amplified 
by PCR using primers that delete the stop codon of the 
receptors and introduce EcoRI and BamHI restriction 
enzyme sites. The resulting A2A and A2BAR PCR products 
were cloned in-frame with EcoRI/BamHI into pRluc-N2. 
The dopamine D2-pRluc-N2 receptor construct was a gift 
from Prof. Franco. The A2AAR cDNA was cloned in-frame 
with EcoRI/AgeI into pEYFP-N1, respectively. For BRET 
experiments Rluc-EYFP was used as a positive control, 
and Rluc alone and EYFP plasmids alone were employed 
as negative controls. For the positive control the cDNA of 
Rluc was amplified by PCR using primers that delete the 
stop codon of the protein and introduce EcoRI and BamHI 
restriction sites. The resulting PCR product was cloned 
in-frame with EcoRI/BamHI into pEYFP-N1 plasmid, 
respectively. For BRET displacement experiments, the 
cDNA of the human A2BAR was cloned with EcoRI/NotI 
into the pcDNA3.1(+) plasmid. 
Transiently transfected HEK293T cells were 
prepared by subcloning the cDNAs of the human A2A and 
A2B AR with HindIII/BamHI into the vector pcDNA3.1(+). 
All restriction enzymes and supplements for the molecular 
biology were obtained at NEB (Frankfurt, Germany). 
DNA and RNA purification kits were obtained at Zymo 
Research (Freiburg, Germany) or Life Technologies 
GmbH (Darmstadt, Germany).
Transient transfection of CHO-K1 cells for 
FRET and BRET experiments
For FRET and BRET experiments CHO-K1 cells 
were transiently co-transfected with constant amounts 
of the receptor-donor DNA (e.g. A2B-GFP² or A2B-Rluc) 
and constant or increasing amounts of receptor-acceptor 
DNA (e.g. A2A-EYFP) using Lipofectamine 2000 
(Thermo Fisher Scientific, Waltham, USA). Moreover 
the receptor-donor DNAs and receptor-acceptor DNAs 
were transfected alone to determine their contribution to 
the detection channels (spectral signature). The cells were 
harvested 24 h after transfection and used for FRET, and 
BRET experiments, respectively. 
FRET experiments analyzed by fluorimetry
FRET experiments were conducted as previously 
described [36]. 20 µg of the transfected cells (100 µl) 
were distributed in duplicates in a black 96-well plate 
with black bottom for fluorescence measurements. The 
fluorescence signals were detected by a Mithras LB 940 
fluorimeter using a 10-nm bandwidth excitation filter 
at 405 nm and 500 nm and 10-nm bandwidth and 25-
nm bandwidth emission filters corresponding to 510 nm 
and 535 nm (GFP2 exication 405 nm, emission 510 nm; 
EYFP exication 500 nm, emission 535 nm). Background 
fluorescence signals from non-transfected CHO-K1 cells 
were substracted. For all experiments the gain settings and 
the read time of 0.1 s were kept identical.
Quantification of FRET signal
Quantification of the FRET signals was performed 
as described by Elder et al. according to a sensitized 
emission method [54]. This method requires correction 
for donor bleed-through (donor fluorophore emission into 
the acceptor channel) and acceptor cross-excitation (direct 
excitation of acceptor fluorophores by donor excitation). 
For that, the contributions of GFP2 and EYFP proteins 
alone to the two detection channels were measured in 
experiments with cells expressing only one of these 
proteins. The spectral signatures of the different receptors 
fused to either GFP2 or EYFP did not significantly vary 
from the determined spectral signatures of the fluorescent 
proteins alone. The donor bleed-through correction 
factor (DER, measured in cells expressing only donor 
fluorophors) and acceptor cross-excitation factor (AER, 
measured in cells expressing only acceptor fluorophores) 






The AER is the ratio of emission into the acceptor 
channel when using donor excitation relative to when 
using acceptor excitation. The DER is the ratio of emission 
into the acceptor channel relative to emission into the 
donor channel, when using donor excitation [54]. The 
corrected FRET signal was then calculated according to 
the following formula [54]: 
* *DA DD AAcFRET I DER I AER I= − −
Different FRET normalisation equations can be 
used to determine the efficiency of the FRET signal. 
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Here we used the NFRET normalizing method according to 
Shyu et al., which takes changes in donor and acceptor 
concentrations into account [55]:    





FRET signal analyses were done in Excel and results 
were displayed using GraphPad Prism 4.
Bioluminescence resonance energy transfer 
(BRET) experiments analyzed by fluorimetry 
BRET experiments were conducted as previously 
described [36]. 20 µg of the transfected cells (100 µl) were 
distributed in duplicates into a black 96-well plate with 
black bottom for fluorescence and a white 96-well plate 
with white bottom for bioluminescence measurements. 
Signals were detected by a Mithras LB 940 fluorimeter 
calculating the integration for bioluminescence using 
filters for 440–500 nm (485 nm maximum emission of 
bioluminescence), and for fluorescence with a filter for 
510–590 nm (530 nm maximum emission of EYFP). 
To confirm equal expression of Rluc and increasing 
expression of EYFP, for each sample bioluminescence 
and fluorescence was measured before starting the 
experiment. EYFP fluorescence was defined as the 
fluorescence of the sample minus the fluorescence of cells 
expressing only Rluc-tagged receptors. For BRET, 5 µM 
coelenterazine-H (PJK, Kleinblittersdorf, Germany) was 
added to the samples and measurements were performed 
after 1 min (net BRET determination) and after 10 min 
(Rluc luminescence quantification). Net BRET was 
defined as the bioluminescence of the sample minus the 
bioluminescence of cells expressing only Rluc-tagged 
receptors. BRET signals were determined by calculating 
the ratio of the light emitted by EYFP over the light 
emitted by the Rluc A. milliBRET unit (mBU) is the 
BRET ratio × 1000. Curves were fitted using nonlinear 
regression. Displacement studies were performed in 
triplicates at a constant BRET ratio, around the BRET50 of 
the A2BAR-Rluc/A2AAR-YFP pair, and increasing amounts 
of the A2BAR. For testing the effects of compounds on 
heteromerization of A2AAR and A2BAR the agonists 
adenosine (100 µM), NECA (100 µM), CGS-21680 (A2AR, 
10 µM), BAY60-6583 (A2BR, 10 µM), and the antagonist 
PSB-603 (A2BR, 500 nM) were added for 60 min to cells 
which expressed A2BAR-Rluc and A2AAR-YFP, around 
the BRET50 value. The final DMSO concentration in these 
experiments was 2.5 % and experiments were performed 
in triplicates. 
In situ proximity ligation assay in the rat brain
The experiments were carried out in accordance 
with the European Directive 2010/63/EU and were 
approved by the Bioethical Committee at Karolinska 
Institutet. Male Sprague-Dawley (derived from the 
licensed animal breeder Charles River, Sulzfeld, 
Germany), weighing between 260–310 g at the beginning 
of the experiment, were used. The animals (n = 5) were 
housed individually in standard plastic rodent cages (25 
cm × 30 cm × 30 cm) in a colony room maintained at 21 
± 1° C and 40–50 % humidity under a 12-hour light-dark 
cycle (lights on at 6:00 am). Rodent food and water were 
available ad libitum. All animals used for the in situ PLA 
neurochemical study were experimentally naive. 
To study the distribution of the adenosine A2A-
A2B heteroreceptor complex in the rat brain the in situ 
proximity ligation assay (in situ PLA) was performed as 
described previously [56]. 
Retroviral transfection
CHO cells stably expressing HA-tagged human A2A 
or A2BARs, or both human A2A and A2BARs were generated 
using a retroviral transfection system [5]. HeLa cells 
stably overexpressing HA-tagged human A2AARs were 
also generated using a retroviral transfection system [5]. 
For generating the A2A-A2B co-expressing cell line, GP
+env 
AM12 cells were co-transfected with 6.75 µg of the 
pQCXIP-A2A vector construct and 3.25 µg of VSV-G using 
Lipofectamine 2000. The supernatant medium containing 
the modified virus was filtered and transferred into a small 
flask of 70% confluent CHO-A2B cells. After infection the 
selection of the CHO-A2A-A2B cells was started after 48 h 
by the addition of 10 µg/ml of puromycin. 
Cell culture
Chinese hamster ovary cells (CHO-K1), GP+ env 
AM12 cells and CHO cells stably expressing human 
A2AARs, HA-tagged human A2AAR or human A2BAR 
were cultured as drecribed previously [5, 57]. CHO cells 
stably co-transfected with human A2AAR and A2BAR 
were maintained in Dulbecco's Modified Eagle Medium 
(DMEM-F12) medium supplemented with 10% (v/v) 
fetal calf serum (FCS), 100 units/ml penicillin, 100 
µg/ml streptomycin, 800 µg/ml G418 and 10 µg/ml 
puromycin at 37° C and 5 % CO2. Human Jurkat-T cells 
natively expressing A2A and A2BARs were cultured in 
RPMI 1640 medium supplemented with 10 % (v/v) fetal 
calf serum (FCS), 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine. HeLa cells natively 
expressing human A2A and A2BARs were cultured in 
DMEM supplemented with 10% (v/v) FCS, 100 units/ml 
penicillin, 100 µg/ml streptomycin. HeLa cells stably 
overexpressing the human HA-tagged A2AAR were 
cultured in the same medium with the addition of 800 µg/ml 
of G418. HEK293T cells were grown in DMEM 
supplemented with 2 mM L-glutamine, 5% (v/v) FCS, 
100 units/ml penicillin, 100 µg/ml streptomycin, and 
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minimal essential medium non-essential amino acid 
solution (1:100) at 37° C in an atmosphere of 5 % CO2. 
All cell culture media and supplements were obtained 
from (Darmstadt, Germany), Sigma-Aldrich (Munich, 
Germany) or Applichem (Darmstadt, Germany).
Membrane preparation
The preparations of CHO and HeLa membranes 
recombinantly (or natively) expressing human A2A and/or 
A2BAR subtypes were performed as previously described 
[5]. Membranes from HEK-A2B or A2A cells, which were 
used for some of the radioligand competition binding 
studies, were purchased from Perkin Elmer (Waltham, 
USA). The preparation of Jurkat-T cell membranes 
was performed as follows: a Jurkat-T cell suspension 
was centrifuged in 50 ml falcon tubes at 200 g, 4° C, 5 
min. The supernatant was discarded and the cell pellets 
were quickly frozen at –80° C. The defrosted pellets 
were then resuspended in ice-cold 25 mM Tris-buffer, 
0.32 M sucrose, 1 mM ethylenediaminetetraacetic 
acid (EDTA), 0.1 mM phenylmethanesulfonylfluoride 
(PMSF), pH 7.4, and homogenized with an Ultra-
Turrax (30 s on ice). The homogenate was centrifuged 
for 10 min at 1000 g at 4° C. The resulting pellets were 
discarded and the supernatant was centrifuged for 1 h 
at 48.000 g at 4° C. Pellets containing the membranes 
were resuspended in aqua bidest., homogenized with 
an Ultra-Turrax (30 s on ice) and centrifuged under the 
same conditions. The supernantant was discarded and the 
pellets were resuspended in 50 mM Tris-buffer, pH 7.4 
and homogenized with a glass Teflon homogenizer on ice. 
The resuspended and homogenzied pellets were aliquoted 
and stored at –80° C until use. The protein content of all 
membrane preparations was determined with the Lowry 
method [58].
Radioligand binding assays
Radioligand receptor binding experiments at 
membrane preparation of native (HeLa) and recombinant 
cells (CHO- or HEK cells recombinantly expressing 
A2A and/or A2BARs) using the A2B-selective antagonist 
radioligand [³H]PSB-603 (spec. activity: 79 Ci/mmol) to 
detect A2BARs were performed as previously described 
[59]. Competition binding experiments at various 
membrane preparations of native (HeLa, Jurkat-T) and 
recombinant cells (CHO or HEK cells expressing A2A and/
or A2BARs) using the A2A-selective antagonist radioligand 
[3H]MSX-2 (spec. activity: 85 Ci/mmol) to detect A2AARs 
were performed in analogy to described procedures [39]. 
The assay was performed in a final volume of 400 µl 
containing 4 µl of test compound dissolved in DMSO, 
196 µl buffer (50 mM Tris-HCl, pH 7.4), 100 µl of 
radioligand solution in the same buffer (1 nM), and 100 
µl of membrane preparation (10 to 200 µg protein per vial, 
2 U/ml adenosine deaminase (ADA) 20 min incubation at 
rt). Non-specific binding was determined in the presence 
of unlabeled MSX-2, or CGS-15943, respectively (10 µM), 
both giving identical results. 
Competition binding experiments at membrane 
preparations of native cells (HeLa, Jurkat-T cells) or 
recombinant cells (CHO, HEK or HeLa recombinantly 
expressing the human A2AAR) using the agonist radioligand 
[3H]CGS-21680 (spec. activity: 39 Ci/mmol) were 
performed in analogy to described procedures [5]. The 
assay was performed in a final volume of 400 µl containing 
4 µl of test compound dissolved in DMSO, 196 µl buffer 
(50 mM Tris-HCl, 10 mM MgCl2 pH 7.4), 100 µl of 
radioligand solution in the same buffer (5 nM), and 100 µl 
of membrane preparation (10 to 200 µg of protein per vial, 
2 U/ml ADA 20 min incubation at rt). Non-specific binding 
was determined in the presence of NECA (10 or 50 µM, 
respectively) or CGS-15942 (final concentration 10 µM); 
all gave identical results. All data were analyzed with 
GraphPad Prism, Version 4 (GraphPad Inc., La Jolla, CA).
Radioligand binding assays at Jurkat-T cell 
membranes
Competition binding experiments at Jurkat-T cell 
membrane preparations using the A2B-selective antagonist 
radioligand [³H]PSB-603 to detect A2BARs were 
performed in a final volume of 1000 µl containing 25 µl 
of test compound dissolved in DMSO/50 mM Tris-buffer 
pH 7.4 (1:1), 375 µl of assay buffer (50 mM Tris-HCl, 
pH 7.4), 100 µl of radioligand solution in the same buffer 
(final concentration 0.3 nM), and 500 µl of membrane 
suspension (100–200 µg protein per vial, 2 U/ml 
20 min incubation at rt). Non-specific binding was 
determined in the presence of unlabeled PSB-603 (10 
nM) or DPCPX (10 µM); both gave similar results. After 
an incubation time of 60 min at rt, the assay mixture was 
filtered through GF/B glass fiber filters. Washing buffer: 
50 mM Tris-HCl buffer, 0.1% bovine serum albumin 
(BSA), pH 7.4. 
cAMP assays
The determination of cAMP accumulation in 
recombinant CHO and in Jurkat-T cells was performed 
as previously described [5, 60]. KB-values for the A2A-
specific antagonist MSX-2, the A2B-specific antagonist 
PSB-603 and the non-selective antagonist caffeine were 
determined versus the full agonist NECA. KB-values were 
calculated using the child equation [61].
Transient transfection of HEK293T cells for 
cAMP assays
HEK293T cells were transiently transfected with the 
corresponding cDNA (pcDNA3.1+-hA2B, pcDNA3.1+-
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hA2A) by the polyethylenimine (Sigma) method [62]. 
The determination of AR-induced cAMP accumulation 
in HEK293T cells transiently expressing A2A and A2BARs 
was performed as previously described [62].
Dynamic mass redistribution assays
Dynamic mass redistribution (DMR) at HEK293T 
cells transfected with A2A and A2BARs was determined 
as described previously [62]. In brief, 24 h before the 
assay, cells were seeded at a density of 7,500 cells per 
well in 384-well sensor microplates with 40 µl of growth 
medium and cultured for 24 h (37° C, 5 % CO2) to obtain 
70–80% confluent monolayers. Prior to the assay, cells 
were washed twice with assay buffer (Hank’s balanced 
salt solution; HBSS with 20 mM HEPES, pH 7.15) and 
incubated for 2 h in 40 µl per well of assay buffer in the 
DMR reader at 24° C. Hereafter, the sensor plate was 
scanned and a baseline optical signature was recorded 
before adding 10 µl of test compound dissolved in assay 
buffer containing 0.1% DMSO and DMR responses 
were monitored for at least 8,000 s using an EnSpire® 
Multimode Plate Reader (PerkinElmer, Waltham, MA, 
USA) by a label-free technology. Data were analyzed 
using EnSpire Workstation Software v 4.10.
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